Back to dashboard
CommercialAdministrativeLow impact

08.01.81e, Tafasitamab-cxix (Monjuvi®)

Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
May 27, 2026
We identified it
Jun 19, 2026
Days to comply
—

Summary

This is a reissue of the Tafasitamab-cxix (Monjuvi®) pharmacy policy, which will become effective May 27, 2026. This appears to be a routine policy reissuance for a specialty oncology medication used to treat certain lymphomas.

Action Required

Action needed
By May 27, 2026: Review updated Tafasitamab-cxix (Monjuvi®) policy at the provided URL to identify any changes in coverage criteria, prior authorization requirements, or documentation needs for this specialty oncology medication. Update billing procedures accordingly if changes are identified.

Related policy hubs